argenx Announces Annual General Meeting of Shareholders on May 2, 2023
17 Mars 2023 - 9:01PM
March
17,
2023
Amsterdam, the
Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that an Annual General Meeting of shareholders will be held at
12:00 PM CET on Tuesday, May 2, 2023 at Hilton Amsterdam Schiphol
at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.
The shareholders and all other persons with
meeting rights are invited to attend the Annual General Meeting of
shareholders. The formal notice of convocation (including
information on attending the meeting in person or by proxy,
requirements for notification and registration for the meeting and
regarding the e-voting system) is available on the argenx website
www.argenx.com and on www.abnamro.com/evoting.
The company’s annual report for the financial
year ended December 31, 2022 is now available on its website
www.argenx.com/investors/financial-reports.
AgendaThe agenda includes the
discussion and adoption of the annual accounts for the 2022
financial year, an advisory vote on the company’s 2022 remuneration
report, the discharge of the directors for their duties performed
in 2022, the proposal to re-appoint Mr. Don deBethizy to the Board
of Directors for a period of two years, renewal of the
authorization of the Board of Directors to issue shares and to
limit or exclude pre-emptive rights in relation thereto, the
proposal to appoint Deloitte Accountants B.V. as the company’s
external auditor for the 2023 financial year.
The full agenda for the meeting as well as all
ancillary documents relevant for the meeting are available via the
argenx website and are also available for inspection at the argenx
offices. A free copy thereof may also be obtained by e-mailing
legal@argenx.com. argenx would like to encourage shareholders to
use the voting by (electronic) proxy option as referred to in the
convocation.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases. Partnering with
leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx developed and is commercializing the first-and-only approved
neonatal Fc receptor (FcRn) blocker in the U.S., Japan, the EU and
the UK. The Company is evaluating efgartigimod in multiple serious
autoimmune diseases and advancing several earlier stage
experimental medicines within its therapeutic franchises. For more
information, visit www.argenx.com and follow us on
LinkedIn, Twitter, and Instagram.
For further information, please
contact:
Media:Erin
Murphyemurphy@argenx.com
Investors:Beth
DelGiaccobdelgiacco@argenx.com
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024
